Research Analysts’ Recent Ratings Changes for CVS Health (CVS)

Posted by ABMN Staff on Mar 5th, 2025

Several analysts have recently updated their ratings and price targets for CVS Health (NYSE: CVS):

2/18/2025 – CVS Health was given a new $77.00 price target on by analysts at Argus.
2/18/2025 – CVS Health had its price target raised by analysts at JPMorgan Chase & Co. from $80.00 to $81.00. They now have an “overweight” rating on the stock.
2/13/2025 – CVS Health had its price target raised by analysts at Wells Fargo & Company from $68.00 to $73.00. They now have an “overweight” rating on the stock.
2/13/2025 – CVS Health had its price target raised by analysts at Barclays PLC from $71.00 to $73.00. They now have an “overweight” rating on the stock.
2/13/2025 – CVS Health was upgraded by analysts at Leerink Partners from a “market perform” rating to an “outperform” rating. They now have a $75.00 price target on the stock, up previously from $55.00.
2/13/2025 – CVS Health was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
2/13/2025 – CVS Health had its price target raised by analysts at Truist Financial Co. from $60.00 to $76.00. They now have a “buy” rating on the stock.
2/12/2025 – CVS Health was upgraded by analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating.
2/12/2025 – CVS Health was upgraded by analysts at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating.
2/11/2025 – CVS Health had its price target raised by analysts at Wolfe Research from 67.00 to 70.00. They now have an “overweight” rating on the stock.
2/11/2025 – CVS Health had its price target lowered by analysts at UBS Group AG from $62.00 to $59.00. They now have a “neutral” rating on the stock.
2/11/2025 – CVS Health had its price target raised by analysts at Leerink Partners from $51.00 to $55.00. They now have a “market perform” rating on the stock.
1/30/2025 – CVS Health was upgraded by analysts at Edward Jones from a “hold” rating to a “buy” rating.
1/27/2025 – CVS Health had its price target raised by analysts at Evercore ISI from $60.00 to $65.00. They now have an “outperform” rating on the stock.
1/6/2025 – CVS Health had its price target lowered by analysts at Truist Financial Co. from $67.00 to $60.00. They now have a “buy” rating on the stock.

CVS Health Trading Down 1.0 %

Shares of NYSE CVS opened at $64.26 on Wednesday. The firm’s 50 day moving average price is $55.14 and its 200-day moving average price is $56.58. The company has a market cap of $81.01 billion, a PE ratio of 17.56, a P/E/G ratio of 0.98 and a beta of 0.61. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $80.75. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81.

CVS Health (NYSE:CVS – Get Free Report) last issued its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. On average, equities research analysts expect that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 4.14%. CVS Health’s dividend payout ratio (DPR) is 72.68%.

Insider Activity at CVS Health

In related news, Director Michael F. Mahoney acquired 30,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were bought at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the transaction, the director now directly owns 39,356 shares in the company, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.24% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MidAtlantic Capital Management Inc. bought a new position in CVS Health during the third quarter valued at approximately $25,000. Legacy Investment Solutions LLC bought a new position in CVS Health in the third quarter worth approximately $31,000. Ridgewood Investments LLC boosted its stake in shares of CVS Health by 255.7% during the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator’s stock worth $28,000 after acquiring an additional 450 shares during the last quarter. Stonebridge Financial Group LLC purchased a new position in shares of CVS Health during the 4th quarter worth $28,000. Finally, RPg Family Wealth Advisory LLC purchased a new position in shares of CVS Health during the 3rd quarter worth $40,000. Institutional investors own 80.66% of the company’s stock.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.